Switch theme
Sign up to access all valuation multiples
Kolmar Korea Co Ltd is a Korea-based company which is mainly engaged in manufacture and sale of cosmetics. It offers various products such as skin care, makeup, hair care, body care and others. The firm is also involved in development and production of pharmaceutical products and quasi-drugs including general medicines, specialized medicines, bioequivalence medicines and others.
2012
n/a
LTM Revenue $1.9B
LTM EBITDA $230M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kolmar Korea has a last 12-month revenue (LTM) of $1.9B and a last 12-month EBITDA of $230M.
In the most recent fiscal year, Kolmar Korea achieved revenue of $1.8B and an EBITDA of $202M.
Kolmar Korea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kolmar Korea valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Profit | $537M | XXX | $508M | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA | $230M | XXX | $202M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $161M | XXX | $141M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $78.0M | XXX | $65.5M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $693M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kolmar Korea's stock price is KRW 83000 (or $60).
Kolmar Korea has current market cap of KRW 1.96T (or $1.4B), and EV of KRW 2.90T (or $2.1B).
See Kolmar Korea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $1.4B | XXX | XXX | XXX | XXX | $3.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kolmar Korea has market cap of $1.4B and EV of $2.1B.
Kolmar Korea's trades at 1.2x EV/Revenue multiple, and 10.4x EV/EBITDA.
Equity research analysts estimate Kolmar Korea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kolmar Korea has a P/E ratio of 18.3x.
See valuation multiples for Kolmar Korea and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 13.1x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.3x | XXX | 21.8x | XXX | XXX | XXX |
| EV/FCF | 85.8x | XXX | -64.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKolmar Korea's last 12 month revenue growth is 12%
Kolmar Korea's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Kolmar Korea's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kolmar Korea's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kolmar Korea and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 44% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kolmar Korea acquired XXX companies to date.
Last acquisition by Kolmar Korea was XXXXXXXX, XXXXX XXXXX XXXXXX . Kolmar Korea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kolmar Korea founded? | Kolmar Korea was founded in 2012. |
| Where is Kolmar Korea headquartered? | Kolmar Korea is headquartered in South Korea. |
| Who is the CEO of Kolmar Korea? | Kolmar Korea's CEO is Mr. Hyun-kyu Choi. |
| Is Kolmar Korea publicy listed? | Yes, Kolmar Korea is a public company listed on KRX. |
| What is the stock symbol of Kolmar Korea? | Kolmar Korea trades under 161890 ticker. |
| When did Kolmar Korea go public? | Kolmar Korea went public in 2012. |
| Who are competitors of Kolmar Korea? | Similar companies to Kolmar Korea include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Kolmar Korea? | Kolmar Korea's current market cap is $1.4B |
| What is the current revenue of Kolmar Korea? | Kolmar Korea's last 12 months revenue is $1.9B. |
| What is the current revenue growth of Kolmar Korea? | Kolmar Korea revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Kolmar Korea? | Current revenue multiple of Kolmar Korea is 1.1x. |
| Is Kolmar Korea profitable? | Yes, Kolmar Korea is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kolmar Korea? | Kolmar Korea's last 12 months EBITDA is $230M. |
| What is Kolmar Korea's EBITDA margin? | Kolmar Korea's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Kolmar Korea? | Current EBITDA multiple of Kolmar Korea is 9.2x. |
| What is the current FCF of Kolmar Korea? | Kolmar Korea's last 12 months FCF is $24.6M. |
| What is Kolmar Korea's FCF margin? | Kolmar Korea's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Kolmar Korea? | Current FCF multiple of Kolmar Korea is 85.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
